Prognosis evaluation model construction method for diffuse large B-cell lymphoma

By combining molecular biological alterations and IPI scores, a prognostic assessment model for DLBCL was constructed, which solves the problem that existing models fail to fully consider molecular biological alterations, and enables accurate prognostic assessment and individualized treatment guidance for DLBCL patients.

CN119007811APending Publication Date: 2024-11-22ZHENJIANG NO 1 PEOPLES HOSPITAL
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411416722.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-11
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing prognostic assessment models for DLBCL fail to adequately consider molecular biological changes, resulting in a significant decrease in assessment efficacy for high-risk patients and making it difficult to comprehensively identify relapsed/refractory patients at initial diagnosis.

Method used

A novel prognostic assessment model for DLBCL based on molecular biological alterations and IPI was constructed. The model detects mutations in the PIM1, EZH2, B2M, KLHL4, CD79b, MYC, and STAT3 genes and combines this with the traditional IPI score. The assessment is performed using the formula IPI-M = 0.461×IPI + 0.442×PIM1 - 0.842×EZH2 - 0.805×B2M + 0.520×KLHL14 + 0.539×CD79b + 0.611×MYC - 1.233×STAT3.

Benefits of technology

It enables more accurate prognostic assessment of DLBCL patients, comprehensively identifies high-risk groups at initial diagnosis, provides individualized treatment guidance, and improves the accuracy of prognostic assessment and its clinical application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119007811A_ABST
    Figure CN119007811A_ABST
Patent Text Reader

Abstract

The invention relates to a construction method of a diffuse large B-cell lymphoma prognosis evaluation model, which comprises the following steps: (1) collecting data required by an IPI evaluation system of a patient, and detecting whether PIM1, EZH2, B2M, KLHL4, CD79b, MYC and STAT3 genes in a sample are mutated or not; (2) assigning an IPI according to an IPI evaluation system scheme; (3) assigning values according to the mutation states of PIM1, EZH2, B2M, KLHL4, CD79b, MYC and STAT3; (4) substituting the IPI score obtained in the step (2) and the scores corresponding to the various gene mutations obtained in the step (3) into a formula, and calculating to obtain an IPI-M value; and (5) grouping according to the IPI-M value calculated in the step (4), and performing prognosis evaluation. The diffuse large B-cell lymphoma prognosis evaluation model is combined with molecular mutation characteristics and fully considers the influence of common gene mutation, so that a patient is comprehensively evaluated during primary diagnosis, important guidance is provided for subsequent treatment of the patient, and the diffuse large B-cell lymphoma prognosis evaluation model has good clinical application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and particularly relates to a method for constructing a prognosis evaluation model for diffuse large B-cell lymphoma. Background Art

[0002] Diffuse large B-cell lymphoma (DLBCL) is an aggressive mature B-cell lymphoma and the most common lymphoma subtype, accounting for 25%-50% of all cases. The clinical heterogeneity of DLBCL patients is large, and the prognosis is also quite different. Based on the first-line standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen, about 60% of patients can achieve clinical cure, and the remaining about 40% of patients develop relapsed / refractory disease. However, it is difficult to completely distinguish and identify relapsed / refractory patients at the initial diagnosis. Therefore, clinical attempts have been made to identify such patients as much as possible through a variety of classification and prognostic evaluation systems, and to provide intensive treatment to improve their prognosis. Previously, the cell of origin (COO) classification was a commonly used classification system in clinical practice, which can be divided into germinal center B cell-like (GCB), activated B cell-like (ABC) and type III. The treatment response of the ABC subtype is significantly lower than that of the GCB subtype, and the prognosis is relatively poor. However, with the deepening of practice, it was found that there was significant heterogeneity within the GCB and ABC subtypes. COO typing alone was insufficient to identify relapsed / refractory patients, and there were many unmet clinical needs. Researchers subsequently also attempted to identify "double-hit" and "double-expression" lymphomas, but they still could not meet clinical needs. In recent years, with the development of biological technology, especially the widespread application of second-generation sequencing technology, researchers have a deeper understanding of the disease, and DLBCL typing has gradually entered the era of typing based on genetic characteristics. In 2018, the molecular classification of DLBCL was first proposed, and DLBCL was divided into four types: MCD, BN2, N1, and EZB. In 2020, it was refined based on the LymphGen algorithm and divided into six types: MCD, N1, A53, BN2, ST2, and EZB, and potential targeted therapies were proposed. In 2023, Chinese scholars simplified the LymphGen molecular classification based on LymphPlex, dividing it into TP53mut, MCD-like, BN2-like, N1-like, EZB-like, and ST2-like, and proposed the R-CHOP+"X" regimen based on molecular classification to improve patient prognosis.

[0003] The International Prognostic Index (IPI), age-adjusted IPI (aaIPI) and the National Comprehensive Cancer Network-revised IPI (NCCN-IPI) assessment model are still the main clinical tools for predicting the prognosis of DLBCL patients. The parameters included in the above assessment models include age, serum lactate dehydrogenase (LDH), physical condition (PS) score, Ann Arbor stage, extranodal involvement sites, and kidney or adrenal involvement. However, such models do not incorporate the patient's molecular biological changes, and the evaluation efficiency of high-risk patients in clinical applications is significantly reduced. Therefore, there is an urgent need for a model based on molecular biological changes to comprehensively evaluate the patient's prognosis. Summary of the invention

[0004] In view of the deficiencies of the above-mentioned existing prognostic evaluation models and clinical needs, the present invention provides a new DLBCL prognostic evaluation model based on molecular biological changes and IPI, and a construction method and application thereof, which are used to more accurately evaluate the prognosis of DLBCL patients under the guidance of current molecular typing.

[0005] The present invention will achieve the above-mentioned invention object through the following technical solutions:

[0006] In one aspect, the present invention provides a method for constructing a prognostic evaluation model for diffuse large B-cell lymphoma, comprising the following steps:

[0007] (1) Collect the data required by the patient's IPI evaluation system and detect whether the PIM1, EZH2, B2M, KLHL4, CD79b, MYC, and STAT3 genes in the sample are mutated; the data required by the patient's IPI evaluation system include the patient's age, serum LDH value, PS score, Ann Arbor stage, and number of extranodal involvement sites;

[0008] (2) Based on the data required by the IPI assessment system collected in step (1), if the age is >60 years old, 1 point is given, otherwise 0 point; serum LDH value is >upper limit of normal value 220 U / L, 1 point is given, otherwise 0 point; physical condition (PS) score ≥2, 1 point is given, otherwise 0 point; Ann Arbor stage ≥III, 1 point is given, otherwise 0 point; the number of extranodal involvement sites is >1, 1 point is given, otherwise 0 point; the sum of the above five results is taken as the IPI score, with a minimum score of 0 and a maximum score of 5;

[0009] (3) When the seven genes detected in step (1) mutate, the scores are calculated according to the following rules: if the PIM1 gene mutates, PIM1=1, otherwise PIM1=0; if the EZH2 gene mutates, EZH2=1, otherwise EZH2=0; if the B2M gene mutates, B2M=1, otherwise B2M=0; if the KLHL4 gene mutates, KLHL4=1, otherwise KLHL4=0; if the CD79b gene mutates, CD79b=1, otherwise CD79b=0; if the MYC gene mutates, MYC=1, otherwise MYC=0; if the STAT3 gene mutates, STAT3=1, otherwise STAT3=0;

[0010] (4) Substitute the IPI score obtained in step (2) and the scores corresponding to various gene mutations obtained in step (3) into the following formula to calculate the IPI-M value:

[0011] IPI-M=0.461×IPI+0.442×PIM1-0.842×EZH2-0.805×B2M+0.520×KLHL14+0.539×CD79b+0.611×MYC-1.233×STAT3;

[0012] (5) Grouping and prognosis assessment were performed according to the IPI-M values ​​calculated in step (4), wherein an IPI-M value ≤ 0.0 was assigned to a very low-risk group, 0.0 < IPI-M value ≤ 0.5 was assigned to a low-risk group, 0.5 < IPI-M value ≤ 1.5 was assigned to a medium-risk group, 1.5 < IPI-M value ≤ 2.0 was assigned to a high-risk group, and an IPI-M value > 2.0 was assigned to a very high-risk group.

[0013] Preferably, the prognostic assessment model is used to predict and assess the overall survival of a subject.

[0014] A second aspect of the present invention provides a diffuse large B-cell lymphoma prognosis risk assessment system, the prognosis risk assessment system comprising:

[0015] (1) Analysis module: The analysis module is used to obtain the subject's IPI score-related data and PIM1, EZH2, B2M, KLHL4, CD79b, MYC, and STAT3 gene mutation data; and

[0016] (2) Evaluation module: The evaluation module assigns corresponding evaluation scores to the acquired IPI score-related data and gene mutation data, obtains the total score according to the calculation formula, and outputs the corresponding prognostic status of the subject to achieve the prognostic risk assessment of diffuse large B-cell lymphoma.

[0017] Preferably, the data related to the subject's IPI score in the analysis module include the subject's age, serum LDH value, PS score, Ann Arbor stage, and number of extranodal involvement sites.

[0018] Preferably, the evaluation module assigns scores to the IPI score-related data according to the following rules: when the age is greater than 60 years old, 1 point is recorded, otherwise 0 point; serum LDH value is greater than the upper limit of normal value 220U / L, 1 point is recorded, otherwise 0 point; PS score ≥2, 1 point is recorded, otherwise 0 point; Ann Arbor stage ≥III, 1 point is recorded, otherwise 0 point; the number of extranodal involvement sites is greater than 1, 1 point is recorded, otherwise 0 point; the sum of the above five results is used as the IPI score.

[0019] Preferably, the evaluation module assigns scoring values ​​to the gene mutation data according to the following rules: if the PIM1 gene mutates, PIM1=1, otherwise PIM1=0; if the EZH2 gene mutates, EZH2=1, otherwise EZH2=0; if the B2M gene mutates, B2M=1, otherwise B2M=0; if the KLHL4 gene mutates, KLHL4=1, otherwise KLHL4=0; if the CD79b gene mutates, CD79b=1, otherwise CD79b=0; if the MYC gene mutates, MYC=1, otherwise MYC=0; if the STAT3 gene mutates, STAT3=1, otherwise STAT3=0;

[0020] Preferably, the calculation formula of the total score IPI-M in the evaluation module is as follows:

[0021] IPI-M=0.461×IPI+0.442×PIM1-0.842×EZH2-0.805×B2M+0.520×KLHL14+0.539×CD79b+0.611×MYC-1.233×STAT3.

[0022] Preferably, the evaluation criteria for the prognostic status in the evaluation module are as follows: IPI-M value ≤ 0.0 is an extremely low-risk group, 0.0<IPI-M value ≤ 0.5 is a low-risk group, 0.5<IPI-M value ≤ 1.5 is a medium-risk group, 1.5<IPI-M value ≤ 2.0 is a high-risk group, and IPI-M value > 2.0 is an extremely high-risk group.

[0023] The third aspect of the present invention provides a gene composition for prognosis assessment of diffuse large B-cell lymphoma, wherein the gene composition comprises mutated PIM1, EZH2, B2M, KLHL4, CD79b, MYC and STAT3 genes.

[0024] A fourth aspect of the present invention provides the use of a reagent for detecting the expression level of a gene composition in the preparation of a diffuse large B-cell lymphoma prognosis kit, wherein the gene composition comprises mutated PIM1, EZH2, B2M, KLHL4, CD79b, MYC and STAT3 genes.

[0025] Beneficial effects of the present invention:

[0026] The present invention combines IPI and gene mutation to construct a prognostic model for evaluating DLBCL. On the basis of the existing IPI model, combined with molecular mutation characteristics, the influence of common gene mutations is fully considered, and PIM1, EZH2, B2M, KLHL4, CD79b, MYC, and STAT3 gene mutation factors are incorporated into the evaluation model, so that DLBCL patients can be comprehensively evaluated at the time of initial diagnosis, providing important guidance for the patient's subsequent treatment, and having good clinical application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 This is a heat map of gene mutations in DLBCL patients;

[0028] Figure 2 The Kaplan-Meier survival curve was used to analyze the effect of gene mutation on the overall survival of DLBCL patients, where ag represents the effect of PIM1, KLHL4, CD79b, MYC, EZH2, STAT3 and B2M gene mutation on overall survival;

[0029] Figure 3 The effects of IPI-M and IPI model scores and groups on the overall survival of DLBCL patients, where a represents the effect of IPI scores on prognosis, b represents the effect of IPI groups on prognosis, c represents the effect of IPI-M scores on prognosis, and d represents the effect of IPI-M groups on prognosis;

[0030] Figure 4 To compare the efficacy of IPI-M and IPI models in prognostic assessment based on the C-index index;

[0031] Figure 5 To compare the prognostic evaluation performance of IPI-M and IPI models by ROC curve;

[0032] Figure 6 The data validation results of the IPI-M model, where a represents the effect of IPI score on prognosis, b represents the effect of IPI grouping on prognosis, c represents the effect of IPI-M score on prognosis, and d represents the effect of IPI-M grouping on prognosis;

[0033] Figure 7 The effect of IPI-M versus proportional model 1 on overall survival of patients with DLBCL in the screening trial;

[0034] Figure 8 Effect of IPI-M versus proportional model 2 on overall survival of patients with DLBCL in a screening trial. DETAILED DESCRIPTION

[0035] Experimental Example 1: Construction of a prognostic evaluation model for diffuse large B-cell lymphoma

[0036] (1) Based on all the case data of DLBCL (Cell 2017) in the Cancer Genome Atlas (TCGA) database, patients with missing IPI information or missing gene mutation information were excluded, and finally 761 DLBCL patients were included. All the clinical information data of the patients were imported into the Statistical Package for Social Sciences (SPSS), and the basic information of the patients was organized as shown in Table 1. At the same time, the gene mutation information of the patients was plotted based on R language. Figure 1 .

[0037] Table 1 Basic information of DLBCL patients

[0038]

[0039]

[0040] (2) Based on SPSS statistical software, we entered the analysis module through analysis → survival function → Cox regression, included the survival time in the time port, the survival status in the status port, and each gene mutation, IPI score and gene rearrangement data in the covariate port, and performed Cox univariate regression analysis to analyze the effects of all variables on patient prognosis. The specific results are shown in Table 2.

[0041] Enter the analysis module through Analysis → Survival Function → Kaplan-Meier, enter the survival time into the time port, the survival status into the status port, and each gene mutation, IPI score and gene rearrangement data into the factor port respectively. The Kaplan-Meier survival curve is used to analyze the impact of each variable on the patient's prognosis. The specific results are shown in Figure 2 .

[0042] Table 2 Effect of different gene mutations on the prognosis of DLBCL patients

[0043]

[0044]

[0045]

[0046] (3) Combined with the results of Cox univariate regression analysis and Kaplan-Meier survival curve analysis in step 2, the variables PIM1, EZH2, B2M, KLHL14, CD79b, MYC, STAT3 gene mutations and IPI scores that have a significant impact on overall survival in the two models were selected, and each variable was assigned a value based on the regression coefficient in the Cox analysis. The IPI-M score of the patient was calculated using the following formula:

[0047] IPI-M=0.461×IPI+0.442×PIM1-0.842×EZH2-0.805×B2M+0.520×KLHL14+0.539×CD79b+0.611×MYC-1.233×STAT3; if a gene mutates, the gene is assigned a value of 1, otherwise the gene is assigned a value of 0.

[0048] (4) According to the IPI-M calculation results, patients were divided into five groups: those with a calculation result ≤ 0.0 were the very low-risk group, those with a calculation result 0.0 < ≤ 0.5 were the low-risk group, those with a calculation result 0.5 < ≤ 1.5 were the medium-risk group, those with a calculation result 1.5 < ≤ 2.0 were the high-risk group, and those with a calculation result > 2.0 were the very high-risk group.

[0049] (5) The Kaplan-Meier survival curve was used to analyze the effects of different IPI-M scores and groupings on the overall survival of patients. The Kaplan-Meier survival curve was also used to analyze the effects of different IPI scores and groupings on the overall survival of patients. Figure 3 As shown in the figure, the prognostic discrimination of IPI-M was significantly higher than that of IPI grouping.

[0050] (6) The consistency of IPI-M in prognostic assessment calculated by C-index is higher than that of IPI stratification (see Figure 4 ), the 1-year, 3-year and 5-year overall survival rates were significantly higher than those of the IPI group (see Figure 5 ).

[0051] (7) The above IPI-M prognostic evaluation model was applied to 135 patients with DLBCL (Nat Med 2018) in the TCGA database. The Kaplan-Meier survival curve was used to analyze the effects of different IPI-M scores and groups on the overall survival of patients. The results showed that the prognostic discrimination of IPI-M was also higher than that of IPI groups (see Figure 6 ).

[0052] Experimental Example 2: Diffuse Large B-cell Lymphoma Prognostic Evaluation Model Mutation Gene Screening Test

[0053] (1) As described in step (2) of Experimental Example 1, the effects of gene mutations and IPI scores on patient prognosis were analyzed by Cox univariate regression, and variables with significant effects on the prognosis of DLBCL patients were screened out (see Table 2). With P < 0.1 as the critical value, PIM1, EZH2, B2M, KLHL14, CD79b, MYC, STAT3 mutations and IPI score variables were screened out and included in the Cox regression multivariate analysis. Specifically, the analysis module was entered through analysis → survival function → Cox regression, and the survival time was included in the time port, and the survival status was included in the status port. At the same time, the above variables were included in the covariate port, and the effects of all variables on patient prognosis were analyzed by Cox multivariate regression. The specific results are shown in Table 3.

[0054] Table 3 Effect of Cox multivariate regression analysis variables on overall survival of DLBCL patients

[0055] variable frequency Hazard ratio (95% CI) Correlation coefficient β P-value IPI - 1.592(1.439-1.761) 0.465 <0.001 PIM1 mutations 14.7%(112 / 761) 1.403(1.014-1.942) 0.339 0.041 EZH2 mutations 5.9%(45 / 761) 0.461(0.202-1.048) -0.775 0.065 B2M mutation 5.5%(42 / 761) 0.477(0.211-1.081) -0.739 0.076 KLHL14 mutation 5.1%(39 / 761) 1.403(0.863-2.280) 0.339 0.172 CD79b mutation 5.4%(41 / 761) 1.398(0.849-2.301) 0.335 0.188 MYC mutation 4.3%(33 / 761) 1.769(1.060-2.953) 0.570 0.029 STAT3 mutations 3.4%(26 / 761) 0.281(0.090-0.882) -1.268 0.030

[0056] (2) Combined with the results of Cox multivariate regression analysis in step (1), the variables PIM1, MYC, STAT3 gene mutations and IPI score that have a significant impact on overall survival were selected, and values ​​were assigned to each variable based on the regression coefficient in the Cox multivariate analysis. The IPI-M score of the patient was calculated using the following formula:

[0057] IPI-M=0.465×IPI+0.339×PIM1+0.570×MYC-1.268×STAT3 (Comparative Model 1); when a gene mutates, the gene is assigned a value of 1, otherwise the gene is assigned a value of 0.

[0058] (3) According to the calculation results of IPI-M proportional model 1, the patients were divided into 5 groups: the calculation result ≤ 0.0 was the very low-risk group, 0.0<the calculation result ≤ 0.5 was the low-risk group, 0.5<the calculation result ≤ 1.5 was the medium-risk group, 1.5<the calculation result ≤ 2.0 was the high-risk group, and the calculation result > 2.0 was the very high-risk group.

[0059] (4) The Kaplan-Meier survival curve was used to analyze the effect of IPI-M on the overall survival of patients compared with model 1. The experimental results are as follows: Figure 7 As shown, according to the Kaplan-Meier survival curve test value, however, its discrimination is not as good as the IPI-M model of the present invention ( Figure 3 d).

[0060] (6) Reenter step 1, but use P < 0.2 as the critical value, screen out PIM1, ARID1A, TP53, GNA13, NOTCH2, ATM, EZH2, B2M, KLHL14, CD79b, MYC, STAT3, DDX3X mutations and IPI score variables and include them in Cox regression multivariate analysis. Specifically, enter the analysis module through Analysis → Survival Function → Cox Regression, include survival time in the time port, and survival status in the status port. At the same time, include the above variables in the covariate port, and perform Cox multivariate regression analysis to analyze the effects of all variables on patient prognosis. The specific results are shown in Table 4.

[0061] Table 4 Effect of Cox multivariate regression analysis variables on overall survival of DLBCL patients

[0062] variable frequency Hazard ratio (95% CI) Correlation coefficient β P-value IPI - 1.602(1.447-1.774) 0.471 <0.001 PIM1 mutations 14.7%(112 / 761) 1.392(1.003-1.931) 0.331 0.048 ARID1A mutations 9.3%(71 / 761) 1.427(0.934-2.180) 0.356 0.100 TP53 mutations 10.1%(77 / 761) 0.978(0.653-1.465) -0.022 0.915 GNA13 mutation 8.9%(68 / 761) 1.481(0.975-2.250) 0.393 0.066 NOTCH2 mutations 7.1%(54 / 761) 1.076(0.681-1.701) 0.074 0.752 ATM mutations 7.0%(53 / 761) 0.620(0.346-1.112) -0.478 0.108 EZH2 mutations 5.9%(45 / 761) 0.417(0.181-0.959) -0.875 0.039 B2M mutation 5.5%(42 / 761) 0.479(0.211-1.085) -0.737 0.078 KLHL14 mutation 5.1%(39 / 761) 1.439(0.882-2.348) 0.364 0.145 CD79b mutation 5.4%(41 / 761) 1.305(0.783-2.175) 0.266 0.307 MYC mutation 4.3%(33 / 761) 1.663(0.995-2.779) 0.509 0.052 STAT3 mutations 3.4%(26 / 761) 0.284(0.091-0.892) -1.257 0.031 DDX3X mutation 3.3%(25 / 761) 0.444(0.161-1.223) -0.811 0.116 CIITA mutation 1.8%(14 / 761) 2.275(1.066-4.852) 0.822 0.033

[0063] (7) Combined with the results of Cox multivariate regression analysis in step (1), with P < 0.05 as the critical value, the variables PIM1, MYC, STAT3 gene mutation and IPI score that have a significant impact on overall survival were selected, and the regression coefficient in the Cox multivariate analysis was used to assign values ​​to each variable. The IPI-M score of the patient was calculated using the following formula:

[0064] IPI-M=0.471×IPI+0.331×PIM1-0.875×EZH2-1.257×STAT3+0.822×CIITA (comparative model 2); when a gene mutates, the gene is assigned a value of 1, otherwise the gene is assigned a value of 0.

[0065] (8) According to the calculation results of IPI-M proportional model 2, the patients were divided into 5 groups: the calculation result ≤ 0.0 was the very low-risk group, 0.0<the calculation result ≤ 0.5 was the low-risk group, 0.5<the calculation result ≤ 1.5 was the medium-risk group, 1.5<the calculation result ≤ 2.0 was the high-risk group, and the calculation result > 2.0 was the very high-risk group.

[0066] (9) The Kaplan-Meier survival curve was used to analyze the effect of IPI-M on the overall survival of patients in proportion model 2. The experimental results are as follows: Figure 8 As shown, according to the Kaplan-Meier survival curve test value, however, its discrimination is not as good as the IPI-M model of the present invention ( Figure 3 d).

[0067] In summary, the present invention establishes a new prognostic evaluation model IPI-M for DLBCL patients, which is used as a method for prognostic evaluation of DLBCL patients to provide support for the precise and individualized treatment of DLBCL in clinical practice.

Claims

1. A method for constructing a prognostic evaluation model for diffuse large B-cell lymphoma, characterized in that: The following steps are involved: (1) Collect the data required by the patient's IPI assessment system and detect whether the PIM1, EZH2, B2M, KLHL4, CD79b, MYC, and STAT3 genes in the sample are mutated; the data required by the patient's IPI assessment system include the patient's age, serum LDH value, physical condition (PS) score, Ann Arbor stage, and number of extranodal involvement sites; (2) Based on the data required by the IPI assessment system collected in step (1), if the age is >60 years old, 1 point is given, otherwise 0 point; serum LDH value is >upper limit of normal value 220 U / L, 1 point is given, otherwise 0 point; PS score is ≥2, 1 point is given, otherwise 0 point; Ann Arbor stage is ≥III, 1 point is given, otherwise 0 point; the number of extranodal involvement sites is >1, 1 point is given, otherwise 0 point; the sum of the above five results is used as the IPI score, with a minimum score of 0 and a maximum score of 5; (3) When the seven genes detected in step (1) mutate, the scores are calculated according to the following rules: if the PIM1 gene mutates, PIM1=1, otherwise PIM1=0; if the EZH2 gene mutates, EZH2=1, otherwise EZH2=0; if the B2M gene mutates, B2M=1, otherwise B2M=0; if the KLHL4 gene mutates, KLHL4=1, otherwise KLHL4=0; if the CD79b gene mutates, CD79b=1, otherwise CD79b=0; if the MYC gene mutates, MYC=1, otherwise MYC=0; if the STAT3 gene mutates, STAT3=1, otherwise STAT3=0; (4) Substitute the IPI score obtained in step (2) and the scores corresponding to various gene mutations obtained in step (3) into the following formula to calculate the IPI-M value: IPI-M=0.461×IPI+0.442×PIM1-0.842×EZH2-0.805×B2M+0.520×KLHL14+0.539×CD79b+0.611×MYC-1.233×STAT3; (5) Grouping and prognosis assessment were performed according to the IPI-M values ​​calculated in step (4), wherein an IPI-M value ≤ 0.0 was assigned to a very low-risk group, 0.0 < IPI-M value ≤ 0.5 was assigned to a low-risk group, 0.5 < IPI-M value ≤ 1.5 was assigned to a medium-risk group, 1.5 < IPI-M value ≤ 2.0 was assigned to a high-risk group, and an IPI-M value > 2.0 was assigned to a very high-risk group.

2. A prognostic risk assessment system for diffuse large B-cell lymphoma, characterized in that: The prognostic risk assessment system comprises: (1) Analysis module: The analysis module is used to obtain the subject's IPI score-related data and PIM1, EZH2, B2M, KLHL4, CD79b, MYC, and STAT3 gene mutation data; and (2) Evaluation module: The evaluation module assigns corresponding evaluation scores to the acquired IPI score-related data and gene mutation data, obtains the total score according to the calculation formula, and outputs the corresponding prognostic status of the subject to achieve the prognostic risk assessment of diffuse large B-cell lymphoma.

3. The prognosis risk assessment system according to claim 2, characterized in that: The data related to the IPI score of the subject in the analysis module include the subject's age, serum LDH value, PS score, Ann Arbor stage, and the number of extranodal involvement sites.

4. The prognosis risk assessment system according to claim 2, characterized in that: In the evaluation module, the IPI score-related data are assigned scores according to the following rules: when the age is greater than 60 years old, 1 point is recorded, otherwise 0 point; when the serum LDH value is greater than the upper limit of the normal value of 220U / L, 1 point is recorded, otherwise 0 point; when the PS score is ≥2, 1 point is recorded, otherwise 0 point; when the Ann Arbor stage is ≥III, 1 point is recorded, otherwise 0 point; when the number of extranodal involvement sites is greater than 1, 1 point is recorded, otherwise 0 point; the sum of the above five results is used as the IPI score.

5. The prognosis risk assessment system according to claim 2, characterized in that: In the evaluation module, the gene mutation data is scored according to the following rules: if the PIM1 gene mutates, PIM1=1, otherwise PIM1=0; if the EZH2 gene mutates, EZH2=1, otherwise EZH2=0; if the B2M gene mutates, B2M=1, otherwise B2M=0; if the KLHL4 gene mutates, KLHL4=1, otherwise KLHL4=0; if the CD79b gene mutates, CD79b=1, otherwise CD79b=0; if the MYC gene mutates, MYC=1, otherwise MYC=0; if the STAT3 gene mutates, STAT3=1, otherwise STAT3=0.

6. The prognosis risk assessment system according to claim 2, characterized in that: The calculation formula of the total score IPI-M in the evaluation module is as follows: IPI-M=0.461×IPI+0.442×PIM1-0.842×EZH2-0.805×B2M+0.520×KLHL14+0.539×CD79b+0.611×MYC-1.233×STAT3.

7. The prognostic risk assessment system according to claim 2, characterized in that: The evaluation criteria for the prognostic status in the assessment module are as follows: IPI-M value ≤ 0.0 is the very low-risk group, 0.0 < IPI-M value ≤ 0.5 is the low-risk group, 0.5 < IPI-M value ≤ 1.5 is the medium-risk group, 1.5 < IPI-M value ≤ 2.0 is the high-risk group, and IPI-M value > 2.0 is the very high-risk group.

8. A gene composition for prognosis assessment of diffuse large B-cell lymphoma, characterized in that: The gene composition comprises mutated PIM1, EZH2, B2M, KLHL4, CD79b, MYC and STAT3 genes.

9. Use of a reagent for detecting the expression level of a gene combination in the preparation of a prognosis kit for diffuse large B-cell lymphoma, characterized in that: The gene composition comprises mutated PIM1, EZH2, B2M, KLHL4, CD79b, MYC and STAT3 genes.

Citation Information

Cited By

  • MDS / AML prognosis evaluation model construction method and application thereof

    CN120977400A

  • Diffuse large B-cell lymphoma prognosis evaluation model based on tumor infiltrating clonal hematopoietic mutation and application

    CN122474132A